Hamel Associates, Inc. Novartis Ag Transaction History
Hamel Associates, Inc.
- $295 Million
- Q2 2025
A detailed history of Hamel Associates, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Hamel Associates, Inc. holds 40,755 shares of NVS stock, worth $5.36 Million. This represents 1.67% of its overall portfolio holdings.
Number of Shares
40,755
Previous 41,060
0.74%
Holding current value
$5.36 Million
Previous $4.58 Million
7.73%
% of portfolio
1.67%
Previous 1.56%
Shares
26 transactions
Others Institutions Holding NVS
# of Institutions
1,560Shares Held
136MCall Options Held
1.72MPut Options Held
1.7M-
Dodge & Cox San Francisco, CA10.6MShares$1.4 Billion0.78% of portfolio
-
Primecap Management CO Pasadena, CA10.4MShares$1.37 Billion1.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX9.06MShares$1.19 Billion0.26% of portfolio
-
Morgan Stanley New York, NY7.56MShares$994 Million0.06% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa7.12MShares$937 Million0.35% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $283B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...